UK Companies House feature
QUANTUM PHARMACEUTICAL LIMITED
Cash
£3M
-4.4% vs 2023
Net assets
—
Equity attributable
Employees
250
-9.4% vs 2023
Profit before tax
£11M
-29.3% vs 2023
Profile
- Company number
- 05240304
- Status
- Active
- Incorporation
- 2004-09-24
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21200
- Hubs
- UK Healthcare
Profit before tax
6-year trend · vs UK Healthcare median
Accounts
6-year trend · latest 2024-12-31
| Metric | Trend | 2019-06-30 | 2020-06-30 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Turnover | — | — | — | — | — | — | |
| Operating profit | — | — | — | — | — | — | |
| Profit before tax | — | — | — | — | £15,983,242 | £11,304,361 | |
| Net profit | — | — | — | — | — | — | |
| Cash | — | — | — | — | £3,469,031 | £3,317,539 | |
| Total assets less current liabilities | — | — | — | — | — | — | |
| Net assets | — | — | — | — | — | — | |
| Equity | — | — | £3,455,518 | £4,688,369 | £15,421,960 | £23,779,568 | |
| Average employees | — | — | — | — | 276 | 250 | |
| Wages | — | — | — | — | £8,227,011 | £8,230,775 |
Values shown as filed in iXBRL accounts. — indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Consilium Audit Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Significant events
- “Turnover for the year ended 31 December 2024 grew by 15% to £200.4m (2023: £174.8m). This growth in revenue has been driven by capital investment made both this year and in the prior period which increased manufacturing capabilities in the year under review.”
- “Operating profit for the year ended 31 December 2024 declined to £12.3m (2023: £17.0m), with the Company's operating profit margin reducing to 6% (2023: 10%). This decline reflects a combination of strategic investment in the cost base and short-term margin pressures.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
3 active · 29 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BARCLAY, Kenneth Edward | Director | 2026-02-06 | Aug 1978 | British |
| CAMPBELL, Lewis | Director | 2021-06-30 | Apr 1993 | British |
| DUNCAN, Stephen Peter | Director | 2021-07-14 | Apr 1986 | Scottish |
Show 29 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| EDGE, Ian | Secretary | 2004-09-24 | 2009-03-30 |
| MILLER, Amanda | Secretary | 2017-11-02 | 2021-06-30 |
| SCAIFE, Andrew John | Secretary | 2009-03-30 | 2010-01-29 |
| SUCH, Martin John | Secretary | 2010-01-29 | 2015-02-24 |
| SWINHOE, Craig Robert | Secretary | 2015-02-24 | 2017-11-02 |
| BARKER, Michael Denis | Director | 2015-06-18 | 2015-12-01 |
| BROWN, Catherine Jane | Director | 2016-03-16 | 2017-09-05 |
| BRYANT, David John | Director | 2019-02-01 | 2021-06-30 |
| BUYER, Victoria | Director | 2011-02-25 | 2011-10-07 |
| DICKINSON, Timothy David | Director | 2011-02-25 | 2013-04-26 |
| EDGE, Ian | Director | 2004-09-24 | 2010-09-08 |
| FISHER, Brian James | Director | 2012-01-27 | 2017-12-22 |
| GRANT, Gillian Margaret | Director | 2022-08-23 | 2025-02-24 |
| HUDSON, Kevin Robert | Director | 2005-04-06 | 2009-01-31 |
| LIDDLE, Stephen | Director | 2017-09-22 | 2018-01-12 |
| MATTHEWS, Andrew Paul | Director | 2011-07-04 | 2019-02-01 |
| MURRAY, Gerard Thomas | Director | 2017-01-23 | 2017-11-02 |
| PALING, Richard John | Director | 2019-03-19 | 2021-06-30 |
| PATTERSON, Andrew | Director | 2004-09-24 | 2009-01-31 |
| RICHARDSON, Phillip Dudley | Director | 2004-09-24 | 2009-01-31 |
| RIGG, Christian Alexander | Director | 2016-03-08 | 2017-01-27 |
| SANSON, David Alan | Director | 2021-07-14 | 2022-05-30 |
| SANSON, David Alan | Director | 2013-09-25 | 2021-06-30 |
| SCAIFE, Andrew John | Director | 2009-01-31 | 2015-12-01 |
| SUCH, Martin John | Director | 2010-01-29 | 2016-03-08 |
| SWINHOE, Craig Robert | Director | 2015-02-24 | 2015-12-01 |
| TAGG, Michael James | Director | 2017-12-01 | 2019-03-19 |
| THOMSON, Graham Ronald | Director | 2017-07-06 | 2018-06-30 |
| WATERS, Alison Anne | Director | 2004-09-24 | 2011-02-25 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Target Healthcare Group Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2022-07-06 | Active |
| Target Healthcare Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-06-30 | Ceased 2022-07-06 |
| Quantum Pharma Group Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Significant influence | 2016-09-24 | Ceased 2021-06-30 |
Filing timeline
Last 20 of 172 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-02-06 | AP01 | officers | appoint person director company with name date |
| 2025-12-15 | CH01 | officers | change person director company with change date |
| 2025-12-15 | CH01 | officers | change person director company with change date |
| 2025-09-30 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-09-26 | AA | accounts | accounts with accounts type full |
| 2025-02-25 | TM01 | officers | termination director company with name termination date |
| 2024-11-06 | CH01 | officers | change person director company with change date |
| 2024-09-24 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-07-05 | AA | accounts | accounts with accounts type full |
| 2024-02-20 | RP04CS01 | confirmation-statement | second filing of confirmation statement with made up date |
| 2024-02-05 | PSC05 | persons-with-significant-control | change to a person with significant control |
| 2023-09-26 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-06-09 | AA | accounts | accounts with accounts type full |
| 2022-09-28 | AA | accounts | accounts with accounts type full |
| 2022-09-26 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2022-09-15 | AP01 | officers | appoint person director company with name date |
| 2022-08-22 | PSC02 | persons-with-significant-control | notification of a person with significant control |
| 2022-08-22 | PSC07 | persons-with-significant-control | cessation of a person with significant control |
| 2022-05-30 | TM01 | officers | termination director company with name termination date |
| 2022-02-21 | MR04 | mortgage | mortgage satisfy charge full |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory